Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
|Articles|August 1, 2001
- Pharmaceutical Technology-08-01-2001
- Volume 2001 Supplement
- Issue 2
Successfully Outsourcing Formulation DevelopmentConsiderations for Emerging Biopharmaceutical Companies
Author(s)Shabbir T. Anik, PhD, Colin M. Minchom, PhD
Successfully taking a new chemical entity from proof-of-concept to commercialization requires the biopharmaceutical company to carefully evaluate a contract services provider's formulation department and ability to become a fully integrated supplier.
Advertisement
Articles in this issue
about 25 years ago
Creating a Successful Partnership with a Contract Manufacturerabout 25 years ago
Outsourcing Outlookabout 25 years ago
Creative Solutions in Client-CRO Relationshipsabout 25 years ago
Third-Party Technology Transferabout 25 years ago
The Squeeze in Contract Manufacturingabout 25 years ago
Stakes Rise for Blown Batchesabout 25 years ago
Partnerships in Drug DiscoveryAdvertisement
Related to this article
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
Can AI Agents Satisfy CGMP Documentation Requirements?
3
PharmTech AI Pulse Check: Fixing AI Slop at the Source
4
Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity
5